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ABSTRACT
Background and Aims: Colorectal cancer (CRC) arises via multiple genetic changes. 
Mutation of the tumour suppressor gene APC, a key regulator of Wnt signalling, is 
recognised as a frequent early driving mutation in CRC. We have previously shown 
that conditional loss of Apc within the murine small intestine (Apcfloxmice) results in 
acute Wnt signalling activation, altered crypt-villus architecture and many hallmarks 
of neoplasia. Our transctipomic profiling (Affymetrix Microarrays) and proteomic 
profiling (iTRAQ-QSTAR) of Apc-deficient intestine inferred the involvement of High 
Mobility Group Box 1 (Hmgb1) in CRC pathogenesis. Here we assess the contribution 
of HMGB1 to the crypt progenitor phenotype seen following Apc loss.
Results: Elevated HMGB1 was confirmed in intestinal epithelia and serum following  
conditional loss of Apc. Treatment of Apcflox mice with anti-HMGB1 neutralising 
antibody significantly reduced many of the crypt progenitor phenotypes associated 
with Apc loss; proliferation and apoptosis levels were reduced, cell differentiation was 
restored and the expansion of stem cell marker expression was eradicated.
Methods: Hmgb1 levels in intestinal epithelia and serum in Apcflox and ApcMin 
mice were assessed using qRT-PCR, Western blot and ELISA assays. The functional 
importance of elevated extracellular Hmgb1 was assessed using an anti-HMGB1 
neutralising antibody in Apcflox mice.
Conclusions: HMGB1 is expressed and secreted from intestinal epithelial cells in 
response to Wnt signalling activation. This secreted HMGB1 is required to maintain 
nearly all aspects of the crypt progenitor phenotype observed following Apc loss and 
add to the body of accumulating evidence indicating that targeting HMGB1 may be a 
viable novel therapeutic approach.
INTRODUCTION
Wnt signalling is a key pathway which regulates 
normal intestinal homeostasis [1]. It is widely recognised 
that deregulation of the Wnt pathway underpins the early 
stages of colorectal cancer [2, 3]. Genetically modified 
mouse models in which the key Wnt regulator and 
tumour suppressor gene Adenomatous polyposis coli 
(Apc) has been rendered inactive, have greatly assisted 
in identifying factors that contribute to the pathogenesis 
of CRC (reviewed [4]). We have previously characterised 
the murine intestine following the conditional deletion of 
Apc, and shown a rapid perturbation of differentiation, 
migration, proliferation, and apoptosis accompanying 
the acute activation of Wnt signalling, such that the 
Apc-deficient cells maintain a “crypt progenitor-
like” phenotype and many hallmarks of neoplasia 
[5]. Furthermore, we have previously conducted 
Transcriptomic Affymetrix microarray analysis [5, 6] and 
proteomic profiling using iTRAQ-QSTAR [7] to identify 
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genes that are mis-regulated at these early stages of 
neoplasia following the loss of Apc, and thereby identify 
factors that potentially contribute to CRC pathogenesis. 
These analyses have inferred the involvement of the High 
Mobility Group Box 1 (Hmgb1) gene.
HMGB1 is an abundant multifunctional protein 
possessing diverse biological activities in normal cells, 
and has been the subject of intense investigation in recent 
cancer research being implicated in tumour formation, 
progression, metastasis and response to chemotherapeutics 
(reviewed [8]). Within the nucleus, HMGB1 functions 
to regulate transcription, replication, DNA repair and 
genomic stability [9–12], while cytoplasmic or cell-
membrane bound HMGB1 can regulate cell motility [13–
15]. Furthermore, HMGB1 can be released by cells, both 
passively and actively, whereupon it can act as a cytokine 
and damage associated molecular pattern (DAMP) 
molecule [16].
HMGB1 is passively released from cells that have 
died in a traumatic, non-programmed way (necrosis or 
pyroptosis) [17, 18]. Significantly, apoptotic cells modify 
their chromatin so as to bind HMGB1, preventing its 
release during this form of programmed cell death [17]. 
Several cell types (including activated immune cells; 
monocytes, macrophages and natural killer cells) have 
the ability to actively secrete HMGB1, via a dedicated 
pathway, and thus produce a damage signal without 
associated cell death [19]. Once released, extracellular 
HMGB1 can interact with a number of different receptors 
including TLR2, TLR4 and RAGE to elicit different 
responses (reviewed [16, 20]). Post-translational 
modifications of HMGB1, particularly in relation to the 
redox state of three cysteines, can influence this receptor 
binding [20]. The all-thiol form of HMGB1 (in which the 
cysteines are reduced) is the predominant intra-cellular 
form and it is this form that is passively released following 
tissue damage. Once released, all-thiol HMGB1 form 
elicits the chemo-attractant activities of HMGB1, via the 
CXCR4 receptor, but this form is not capable of inducing 
cytokine production [21]. Conversely, disulphide-
HMGB1 promotes activation of the NF-κB pathway 
and proinflammatory cytokine production in fibroblasts 
and macrophages [21]. Both the all-thiol and disulphide 
forms of HMGB1 are actively secreted by immune 
cells, but oxidation of the extra-cellular all-thiol form by 
reactive oxygen species (ROS) results in accumulation of 
disulphide and oxidised forms of HMGB1 [21].
Elevated levels of HMGB1 have been reported for 
numerous cancers, including CRC, and higher levels of 
HMGB1 has been show to positively correlate with tumour 
invasion and metastasis (both distant and lymph-node), 
and reduced survival for CRC patients [22, 23]. Indeed, 
7 out of 14 datasets in the Oncomine database display a 
>2 fold up-regulated of HMGB1 (p<0.05) for the cancer 
v normal comparison for colorectal cancer, while, one 
of the four cohorts detailed on Prognoscan (contributed 
by Staub) displays a statistical significant association 
between the levels of HMGB1 and clinical outcome 
(high levels of HMGB1 being associated with a poor 
prognosis. Both databases accessed 25/5/16). Moreover, 
elevated levels of serum HMGB1 are associated with the 
onset of inflammation following the administration of 
dextran sulfate sodium salt (DSS) in a mouse model of 
colitis-associated cancer (DSS-treated ApcMinmice) [24]. 
Administration of a neutralizing anti-HMGB1 antibody in 
this mouse model markedly reduced the level of intestinal 
inflammation and decreased tumour incidence and size, 
thereby highlighting the potential usefulness of HMGB1 
as a target for the treatment of colitis and the prevention 
of colitis-associated cancer [24]. Furthermore, loss of 
the RAGE receptor significantly impacts on intestinal 
tumourigenesis in ApcMin mice [25].
Here we demonstrate that elevated levels of 
HMGB1 occur within the intestine and the serum, 
following the conditional deletion of Apc and acute 
activation of Wnt signalling in the mouse intestine (using 
Apcflox mice). We further show that treatment of Apcflox 
mice with a neutralizing anti-HMGB1 antibody restores 
many of the aberrant features associated with loss of 
Apc toward normal. The exact mechanisms by which 
HMGB1 regulates Wnt signalling and intestinal stem cells 
remains to be determined, however, our work adds to the 
accumulating evidence implicating HMGB1 has potential 
for cancer therapy.
RESULTS
Wnt signalling activation results in up-regulated 
Hmgb1 expression
Apc is a known key regulator of Wnt signalling, 
and critically important in regulating normal intestinal 
homeostasis. Cre-LoxP driven recombination of Apc 
within the mouse intestine using an Ah-Cre recombinase 
to drive recombination of LoxP flanked Apc alleles, 
has previously been shown to result in acute activation 
of Wnt signalling and many hallmarks of neoplasia, 
including increased proliferation and apoptosis and 
loss of differentiation and migration [5]. Our previous 
Affymetrix microarray analysis [5, 6] and proteomic 
profiling using iTRAQ-QSTAR [7] analysis inferred the 
involvement of High Mobility Group Box 1 (Hmgb1). 
Subsequently, upregulation of Hmgb1 expression and 
elevation of HMGB1 within the intestinal epithelia was 
confirmed and shown to occur concomitantly with nuclear 
accumulation of β-catenin (and hence Wnt signalling 
activation) following the conditional loss of Apc (Figure 
1). It is of interest to note that a Tcf binding element (TBE 
sequence [at][at]CAA[at]G) can be found within the 
human HMGB1 promoter [26], which combined with our 
data indicates Hmgb1 is likely a Wnt target gene.
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Different post-translational modifications of 
HMGB1 are known to be associated with different modes 
of release, and extra-cellular functions [21, 27]. ELISA 
analysis confirmed the significant elevation of HMGB1 
levels in mouse serum day 5 post induction of Apc loss 
(Figure 2A), although the cellular source for this secreted 
HMGB1 is not known. These levels are similar to those 
seen in aged (approximately 6 months old) ApcMin mice 
possessing an intestinal tumour burden, but due to 
a greater variability in aged ApcMin mice, significant 
elevation in these samples could not be proven (Figure 
2A). To further characterise the form of the secreted 
HMGB1, tandem mass spectrometry (MS/MS) analysis 
from Apc+/+ (control) and Apcfl/fl serum, Day 4 post 
induction was undertaken (Figure 2B). This demonstrated 
the acquisition of hyper-acetylated and methylated forms 
of HMGB1 following Apc loss, both of which are forms 
that are associated with release due to inflammasome 
activation, pyroptosis and leukocyte and neutrophile 
derived HMGB1 (reviewed [27]). Thus, activation of Wnt 
signalling within the intestinal epithelia leads to the active 
secretion of HMGB1, and significantly higher levels of 
HMGB1 in the serum.
Figure 1: Accumulation of intestinal Hmgb1 following the loss of Apc. A. H+E stained intestine and β-catenin IHC following 
the conditional loss of Apc. Days post induction are indicated at the top. Elevated nuclear accumulation of β-catenin occurs from day 3 PI 
onward. B. Western Blot analysis of HMGB1 levels on triplicate epithelia cell extracts from each time point. Elevation of HMGB1 was 
first seen at day 3 PI. C. qRT-PCR of Hmbg1 expression levels presented as relative fold change within epithelia cell extracts compared to 
day 1 WT demonstrates a significant (*) induction 4 days PI (determined using Whitney U test of ΔCT values at P < 0.05). D. qRT-PCR of 
Hmbg1 expression levels presented as ΔCT values from control (wildtype) and Apc deficient intestinal organoid cultures. The values shown 
represent a 1.9 fold over-expression of Hmgb1 in the Apc deficient organoids.
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Neutralising anti-HMGB1 treatment mitigates 
the Apcflox phenotype and reduces pro-
inflammatory signals
The functional significance of the elevated extra-
cellular HMGB1 levels seen following intestinal Wnt 
signalling activation was assessed by treating induced 
Apcflox mice with neutralising anti-HMGB1 antibody 
for two days prior to sample collection. Although this 
treatment regime did not alter the levels of HMGB1 
within intestinal epithelial cell extracts, the levels of total 
HMGB1 seen within the whole intestine was significantly 
reduced (Figure 3A). Characterisation of the intestinal 
histology revealed that the extent of the “floxed” region 
associated with the loss of Apc was significantly reduced 
following neutralising anti-HMGB1 antibody treatment 
(Figure 3B). Furthermore, microscopic scoring and 
Immunohistochemical (IHC) analysis clearly showed 
a significant reduction in the level of epithelia cell 
proliferation (Figure 3C, 3D) and apoptosis (Figure 
3E) within the “floxed” region, while the activation of 
stem cell markers was significantly reduced (Figure 3F) 
and goblet cell differentiation was restored to normal 
(Supplementary Figure 1). Thus, the extra-cellular 
levels of HMGB1 positively contribute to the phenotype 
observed following the loss of Apc within the intestinal 
epithelia. qRT-PCR analysis has shown a significant 
reduction in the HMGB1 receptor RAGE (1.8 fold down), 
in the whole intestinal tissue from Apcflox treated with 
neutralising anti-HMGB1 antibody compared to those 
treated with control IgY (Figure 4). The importance of 
the HMGB1-RAGE signalling pathway in initiation of 
intestinal tumourigenesis has previously been described 
and a positive feedback loop between ligand and receptor 
signalling proposed [25]. Our results corroborate these 
findings, showing reduction in the levels of the ligand 
HMGB1, results in the reduction in the levels of RAGE 
receptor, and an overall normalisation of the Wnt 
signalling induced “crypt-Progenitor like” phenotype. 
Furthermore, qRT-PCR analysis using whole intestinal 
tissue has shown a significant reduction in the pro-
inflammatory marker and Wnt signalling target gene CD44 
(2.7 fold down) and cytokine Il6 (10.5 fold down) in the 
Apcflox treated with neutralising anti-HMGB1 antibody 
compared to those treated with control IgY (Figure 4). 
However, generic alteration of Wnt signalling target 
genes was not seen; levels of cMYC, PPARdelta, Tcf7, 
Lef1, Fgf4, MMP7 and Wisp1 were not affected by the 
neutralising anti-HMGB1 antibody in the Apcflox intestine.
DISCUSSION
Here we show that activation of Wnt signalling, a 
common and often early event in intestinal tumourigenesis, 
results in the up-regulation and active secretion of Hmgb1 
within the intestine, which in turn results in elevated levels 
of serum Hmgb1. It is likely that release of HMGB1 
signals via the RAGE receptor and promotes inflammation 
activation, which in turn feeds-back to the mechanisms 
regulating normal intestinal homeostasis and the stem cell 
Figure 2: Elevation of serum HMGB1 following the loss of Apc. A. ELISA analysis demonstrating significant elevation of 
HMGB1 serum levels in Apcflox mice and increased levels in ApcMin mice compared to aged match mice. B. Table showing the number 
of samples in which the different post-translational forms of HMGB1 were detected in the serum of Apcflox mice day 4 PI, using MS/MS 
analysis. Empty boxes indicate this form was not detected in any of the samples analysed (n=3).
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compartment within the intestinal epithelia. The process of 
inflammation driven intestinal repair is known to promote 
a tumour-promoting environment [24, 28], and the release 
of HMGB1 contributes to tumourigenesis in mouse models 
of colitis-associated cancer [24, 25, 29].
However, we have also shown that elevated levels 
of Hmgb1 contribute towards many of the abnormal 
“crypt progenitor” phenotypes that occur following the 
loss of Apc, including the expansion of intestinal stem 
cell marker expression. The exact mechanisms by which 
Hmgb1 influences the intestinal stem cells remains to 
be elucidated, but the lack of generic alteration of Wnt 
signalling target genes following the neutralising antibody 
treatment despite the fact that HMGB1 has also been 
shown to be a “non-core regulator” and strong inducer of 
Wnt/TCF-dependent transcription [30], suggests altered 
Wnt signaling is not the likely underlying mechanism. 
Rather the influence of Hmgb1 on immune cells and the 
inflammatory response could be a contributing factor. 
However, our work provides evidence that Hmgb1 is a 
potential Wnt signalling target gene and contributes to the 
body of evidence implicating Hmgb1 in cancer formation 
with the potential for exploitation as a therapeutic target.
Figure 3: Characterisation of Wnt activated intestine following neutralising HMGB1-antibody treatment. A. Western 
blot analysis for total HMGB1 levels in the whole intestine and epithelial cell extracts. Densitometry analysis shows a significant (40%) 
reduction of HMGB1 protein level in the small intestine tissue, but no change in the epithelia cell extracts small intestine epithelial cells. B. 
The length from the base of a crypt to the top of the aberrant morphology displaying crypt-like features was significantly shorter following 
the treatment with neutralising HMGB1-antibody. C. Percent of mitotic bodies within the “floxed” region, D. percent of BRDU and 
Ki67 positive cells within the “floxed” region, and E. percent of apoptotic bodies within the “floxed” region are all significantly reduced 
following neutralising HMGB1-antibody treatment. F. Olfm4 In situ Hybridisation shows a marked reduction within the “floxed” region in 
Apcflox mice following neutralising HMGB1-antibody treatment. In all cases * denotes p<0.05, M-W U test.
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MATERIALS AND METHODS
Mice and sample preparation
This study received ethical approval from Cardiff 
University’s Animal Welfare and Ethical Review Body 
(previously known as the ERP), and all animal procedures 
were conducted in accordance with UK Home Office 
regulations. AhCre+Apc+/+ (control) and AhCre+Apcfl/fl mice 
were generated and maintained on an outbred background 
as previously described [5]. Cre-recombinase activity 
was induced from the Ah-Cre transgene by three intra-
peritoneal (IP) injections of 80 mg/kg β-naphthoflavone 
within 24 h on day 0. Mice were sacrificed, and samples 
collected on the appropriate day post induction as 
previously described [5].
Mice received 225 mg of either anti-Hmgb1 
antibody or the control IgY (products ST326052233, 
IBL International GmbH), IP daily on days 2 and 3 post-
induction, and sacrificed on day 4 (n=4 in each cohort). 
Where appropriate, 250μl BrdU (Amersham) was 
administered via IP injection 2 hrs before sacrifice.
Phenotypic characterisation of intestinal sections
Immunohistochemistry (IHC) was performed on 
paraffin embedded tissues fixed in 4% formaldehyde at 
4°C for no more than 24 hours prior to processing. The 
following antibodies were used for IHC: BrdU 1:500 BD 
biosciences; Ki671:100 Vector Labs ; Caspase 3 1:750 
R&D systems; β-catenin 1:50 C19220, Transduction 
Laboratories.
Crypt length from the base of a crypt to the top of 
the aberrant morphology displaying crypt-like features 
was measured along 50 clear crypt/villus axes for each 
sample. Apoptosis and mitotic index were scored from 
H&E stained sections as previously described [5].
Western analysis
Protein was extracted (from 50-100 mg tissue) 
using RIPA lysis buffer and protein concentrations 
determined (BCA kit, Pierce). 60μg of cellular protein was 
separated on a 10% polyacrylamide gel and transferred to 
nitrocellulose (Schleicher&Schuell). Following a blockinf 
step (TBS containing 5% non fat dry milk, 2% donkey 
Figure 4: Expression analysis of inflammatory response genes in Wnt activated intestine following neutralising 
HMGB1-antibody treatment. Relative fold-change of a panel of inflammatory response genes in whole intestinal extracts following 
the loss of Apc compared to control (top panel) and in Apcflox mice following neutralising HMGB1-antibody treatment compared to control 
IgY treatment. * denotes significance determined using Whitney U test of ΔCT values at P < 0.05.
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serum, 0.02% TX-100, 0.02% NaN3) the following 
antibodies were used: anti-HMGB1 1:1,000 (TECAN), 
mouse anti-actin (ICN) 1:1,000; HRP-conjugated 
secondary donkey antibodies (Diagnostics Scotland) 
1:5,000. SuperSignal West Femto ECL reagent (Pierce) 
was used for detection.
qRT_PCR
RNA extracted from whole intestinal samples, 
was used to synthesise first strand cDNA using a 
VersoTM cDNA Kit (Thermo Scientific) and anchored 
oligo-dT primers (Thermo Scientific) according to the 
manufacturer’s instructions. All qRT-PCR reactions were 
run on the Applied Biosystems StepOnePlus machine. The 
programming was carried out using the computer-based 
StepOnePlus software. Primers were designed using the 
Universal ProbeLibrary Assay Design Centre (Roche).
ELISA and MS/MS analysis
Immediately following cervical dislocation, blood 
was collected directly from the chest cavity and transferred 
into anti-clotting tubes (Sarstedt), kept on ice for a 
minimal time, then centrifuged at full speed for 2min to 
separate serum and cell pellets. Serum was transferred into 
fresh tubes and snap-frozen in liquid nitrogen. HMGB1 
protein in serum was quantified by ELISA (Shino-Test 
Corp.) following the manufacturer's instructions. Mass 
Spectrometric characterisation of HMGB1 (MS/MS) was 
conducted as previously described [31–33].
List of abbreviations used (if any)
Colorectal cancer (CRC); Adenomatous polyposis 
coli (APC); High Mobility Group Box 1 (Hmgb1); Tandom 
Mass spectrometry (MS/MS); Tcf binding element (TBE); 
Intra-peritoneal (IP); Immunohistochemistry (IHC); 
dextran sulfate sodium salt (DSS); reactive oxygen species 
(ROS).
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